Israeli-made dietary supplement fights off viruses in lab tests, scientists say
Mixture of 3 food supplements, each approved by the FDA, appears to be ‘very capable of inhibiting replication of RNA viruses in a remarkable way,’ says researcher behind study
Nathan Jeffay is The Times of Israel's health and science correspondent
Israeli scientists say a special food supplement containing zinc, copper and chemicals that are found in fruit may help fight viruses, after they managed to inhibit virus replication in lab tests.
“We have a mixture of ingredients, each of which is already approved by the FDA as a food supplement, and together appear very capable of inhibiting replication of RNA viruses in a remarkable way,” Prof. Daniel Segal, from Tel Aviv University’s biomedicine school, told The Times of Israel.
However, he acknowledged that the peer-reviewed research took place in-vitro and gave no firm indication so far of what impact on humans the supplements may have.
Segal said that the mixture was tested in the lab on cells from human lungs and elsewhere, along with RNA viruses including those that cause flu and the common cold. Scientists found that virus replication was decreased by at least 50 percent compared to normal circumstances.
Beyond the zinc and copper, the compounds in the supplement are flavonoids, which are found in certain fruits and vegetables and are considered safe as a supplement.
Zinc is known to have anti-viral qualities, but also to struggle to enter cells. The other ingredients in the new supplement appear to bolster its ability to do so, Segal said.
SARS-CoV-2, the RNA virus that causes COVID-19, hasn’t yet been tested, but Segal said he is optimistic its replication may also be slowed given results on other viruses from the coronavirus family.
Segal and his colleagues wrote in their study, which was published in the journal Pharmaceuticals: “Such an inexpensive combination of dietary supplements would be highly advantageous to have, alongside vaccines, as a safe prevention method affecting various RNA respiratory viruses.”
Prof. Ehud Gazit, head of Tel Aviv University’s Blavatnik Center for Drug Discovery and part of the study, commented: “These results are very promising, possibly enabling the development of an orally administered treatment.”
He said that such a product would reflect an “important step forward,” as it would be safe, natural, and potentially effective against a range of viruses and variants.